CheckMate 9DW: Ipi/Nivo as First-Line Treatment for uHCC

(5:37)

CheckMate 9DW: the future of checkpoint inhibitors in advanced HCC

(1:36)

CheckMate 9DW Expanded Analyses: Nivo/Ipi Versus Len/Sor as 1L Therapy for uHCC

(2:22)

CheckMate 9DW, 8HW, NEST, and Bot/Bal

(4:42)

First-Line Nivolumab/Ipilimumab Improves Survival in Unresectable Hepatocellular Carcinoma

(4:46)

Update from ESMO 2024: Immunotherapy (IO) for HCC

(3:49)

Dr Liao on Selecting Between First-Line Monotherapy and Combination Approaches in HCC

(1:58)

Advances and challenges in treatments for hepatocellular carcinoma

(3:39)

Groundbreaking Advances in Liver Cancer Treatment Discussed at ASCO 2024

(39:12)

CheckMate-9ER Discussion: Depth of Response With First-Line Cabozantinib/Nivolumab

(3:35)

CheckMate-9LA: Histology and Frontline Impact

(8:3)

Choosing efficacious treatment options for hepatocellular carcinoma

(2:32)

CheckMate-77T (Periop Nivolumab) vs. CheckMate-816 (Neoadj Nivolumab) - WCLC 2024 Highlights

(5:35)

CheckMate 920: nivo plus ipi for advanced RCC with brain metastases

(3:28)

CheckMate 9LA: First-line nivolumab + ipilimumab + 2 cycles chemotherapy vs 4 cycles chemo in aN...

(4:5)

CheckMate 8HW: Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

(4:21)

ASCO GI Studies to Monitor

(3:27)

CheckMate 274: Estimating the Underlying Cure Fraction for Patients With High-Risk MIUC

(3:43)